GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Adial Pharmaceuticals Inc (NAS:ADILW) » Definitions » EV-to-EBITDA

Adial Pharmaceuticals (Adial Pharmaceuticals) EV-to-EBITDA : 0.00 (As of May. 22, 2024)


View and export this data going back to 2018. Start your Free Trial

What is Adial Pharmaceuticals EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Adial Pharmaceuticals's enterprise value is $0.00 Mil. Adial Pharmaceuticals's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 was $-6.46 Mil. Therefore, Adial Pharmaceuticals's EV-to-EBITDA for today is 0.00.

The historical rank and industry rank for Adial Pharmaceuticals's EV-to-EBITDA or its related term are showing as below:

ADILW' s EV-to-EBITDA Range Over the Past 10 Years
Min: -13.34   Med: 0   Max: 0.11
Current: -0.65

During the past 9 years, the highest EV-to-EBITDA of Adial Pharmaceuticals was 0.11. The lowest was -13.34. And the median was 0.00.

ADILW's EV-to-EBITDA is ranked worse than
100% of 456 companies
in the Biotechnology industry
Industry Median: 10.52 vs ADILW: -0.65

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-22), Adial Pharmaceuticals's stock price is $0.0009. Adial Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was $0.000. Therefore, Adial Pharmaceuticals's PE Ratio for today is N/A.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


Adial Pharmaceuticals EV-to-EBITDA Historical Data

The historical data trend for Adial Pharmaceuticals's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Adial Pharmaceuticals EV-to-EBITDA Chart

Adial Pharmaceuticals Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBITDA
Get a 7-Day Free Trial Premium Member Only -2.21 -1.84 -2.87 -0.18 -0.04

Adial Pharmaceuticals Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.74 -0.56 -0.40 -0.04 -0.06

Competitive Comparison of Adial Pharmaceuticals's EV-to-EBITDA

For the Biotechnology subindustry, Adial Pharmaceuticals's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Adial Pharmaceuticals's EV-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Adial Pharmaceuticals's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Adial Pharmaceuticals's EV-to-EBITDA falls into.



Adial Pharmaceuticals EV-to-EBITDA Calculation

Adial Pharmaceuticals's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=0.000/-6.464
=0.00

Adial Pharmaceuticals's current Enterprise Value is $0.00 Mil.
Adial Pharmaceuticals's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-6.46 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Adial Pharmaceuticals  (NAS:ADILW) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Adial Pharmaceuticals's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=0.0009/0.000
=N/A

Adial Pharmaceuticals's share price for today is $0.0009.
Adial Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.000.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


Adial Pharmaceuticals EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Adial Pharmaceuticals's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Adial Pharmaceuticals (Adial Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
1180 Seminole Trail, Suite 495, Charlottesville, VA, USA, 22901
Adial Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company develops prescription medications for addiction and related disorders. Its lead product is AD04, which is for the treatment of alcohol use disorder.

Adial Pharmaceuticals (Adial Pharmaceuticals) Headlines

From GuruFocus

Adial Pharmaceuticals Schedules Business Update Conference Call

By sperokesalga sperokesalga 03-02-2023